ERBB2 and breast carcinoma: The pilot study in 34 breast cancer patients showed that 99mTc-HP-Ark2 SPECT/CT could noninvasively reflect the status of HER2 in breast cancer, which showed great potential to identify patients to receive trastuzumab treatment and monitor the therapeutic efficacy earlier during trastuzumab treatment.